Your shopping cart is currently empty

GSK-3β/HDAC-IN-1 (Compd 4) is a pioneering non-ATP competitive inhibitor that can penetrate the blood-brain barrier, targeting glycogen synthase kinase 3β/histone deacetylases (GSK-3β/HDACs). It exhibits IC50 values of 0.142 μM for GSK-3β, 0.03 μM for HDAC2, and 0.045 μM for HDAC6. GSK-3β/HDAC-IN-1 is utilized in Alzheimer's research.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | GSK-3β/HDAC-IN-1 (Compd 4) is a pioneering non-ATP competitive inhibitor that can penetrate the blood-brain barrier, targeting glycogen synthase kinase 3β/histone deacetylases (GSK-3β/HDACs). It exhibits IC50 values of 0.142 μM for GSK-3β, 0.03 μM for HDAC2, and 0.045 μM for HDAC6. GSK-3β/HDAC-IN-1 is utilized in Alzheimer's research. |
| Targets&IC50 | HDAC6:0.045 μM, HDAC2:0.03 μM, GSK-3β:0.142 μM |
| Formula | C20H15N3O4S |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.